Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
Marc Peeters(University of Antwerp), R. Sidhu(Amgen (United States)), Yevhen Hotko(Ghent University Hospital), Cornelis J.A. Punt(Utrecht University), Florian Lordick(Leipzig University), G. Wilson(Ghent University Hospital), Timothy Price(Basil Hetzel Institute), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Thierry André(Inserm), Michel Ducreux(Université Paris-Saclay), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Yong‐Sheng Tian, Andrés Cervantes(INCLIVA Health Research Institute), Emily Chan(Ghent University Hospital), A. H. Strickland(Monash Medical Centre), Laslo Roman(Ghent University Hospital), Alberto Sobrero(Ospedale Policlinico San Martino)
Cited by 220
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gastric cancer
|The Lancet|2020|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k